A citation-based method for searching scientific literature

Maria Rosaria Rizzo, Michelangela Barbieri, Raffaele Marfella, Giuseppe Paolisso. Diabetes Care 2012
Times Cited: 208







List of co-cited articles
659 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
25

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
22

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
21

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
19

Mean amplitude of glycemic excursions, a measure of diabetic instability.
F J Service, G D Molnar, J W Rosevear, E Ackerman, L C Gatewood, W F Taylor. Diabetes 1970
823
18

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
Raffaele Marfella, Michelangela Barbieri, Rodolfo Grella, Maria Rosaria Rizzo, Giovanni Francesco Nicoletti, Giuseppe Paolisso. J Diabetes Complications 2010
74
17

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
171
13

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.
Antonio Ceriello, Katherine Esposito, Ludovica Piconi, Michael A Ihnat, Jessica E Thorpe, Roberto Testa, Massimo Boemi, Dario Giugliano. Diabetes 2008
693
13

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
124
11

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
B Guerci, L Monnier, P Serusclat, C Petit, P Valensi, D Huet, D Raccah, C Colette, S Quéré, S Dejager. Diabetes Metab 2012
53
20

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
M Barbieri, M R Rizzo, R Marfella, V Boccardi, A Esposito, A Pansini, G Paolisso. Atherosclerosis 2013
103
10

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
André J Tremblay, Benoît Lamarche, Carolyn F Deacon, S John Weisnagel, Patrick Couture. Metabolism 2014
82
12

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
266
10

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
9

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
9


Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Junichi Matsubara, Seigo Sugiyama, Eiichi Akiyama, Satomi Iwashita, Hirofumi Kurokawa, Keisuke Ohba, Hirofumi Maeda, Koichiro Fujisue, Eiichiro Yamamoto, Koichi Kaikita,[...]. Circ J 2013
141
9


Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Nasib Ervinna, Tomoya Mita, Eisuke Yasunari, Kosuke Azuma, Rica Tanaka, Satoshi Fujimura, Dewi Sukmawati, Takashi Nomiyama, Akio Kanazawa, Ryuzo Kawamori,[...]. Endocrinology 2013
122
8


Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Keisuke Kosugi, Yutaka Umayahara, Tsunehiko Yamamoto,[...]. Diabetes Care 2016
94
8

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
7

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Yanmei Zeng, Chenzhong Li, Meiping Guan, Zongji Zheng, Jingjing Li, Wenwei Xu, Ling Wang, Feiying He, Yaoming Xue. Cardiovasc Diabetol 2014
91
7

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara,[...]. Diabetes Care 2016
91
7

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
7

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
7




A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation.
Jixin Zhong, Xiaoquan Rao, Jeffrey Deiuliis, Zachary Braunstein, Vimal Narula, Jeffrey Hazey, Dean Mikami, Bradley Needleman, Abhay R Satoskar, Sanjay Rajagopalan. Diabetes 2013
112
6




Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction.
Gong Su, Shu-hua Mi, Hong Tao, Zhao Li, Hong-Xia Yang, Hong Zheng, Yun Zhou, Lei Tian. Diabetes Care 2013
84
7


DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata,[...]. Cardiovasc Diabetol 2014
84
7

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Bo Ahrén, Mona Landin-Olsson, Per-Anders Jansson, Maria Svensson, David Holmes, Anja Schweizer. J Clin Endocrinol Metab 2004
517
6

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
6

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
6

The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.
Hwan-Jin Hwang, Hye Soo Chung, Tae Woo Jung, Ja Young Ryu, Ho Cheol Hong, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Dong Seop Choi,[...]. Mol Cell Endocrinol 2015
32
18

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra,[...]. JAMA 2019
163
6


Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Pablo Aschner, Mark S Kipnes, Jared K Lunceford, Matilde Sanchez, Carolyn Mickel, Debora E Williams-Herman. Diabetes Care 2006
631
5

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
392
5

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
207
5

Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
Ioanna Zografou, Christos Sampanis, Eugenia Gkaliagkousi, Fotios Iliadis, Athanasios Papageorgiou, Panagiotis Doukelis, Konstantinos Vogiatzis, Stella Douma. Hormones (Athens) 2015
20
25

Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.
Annayya R Aroor, James R Sowers, Guanghong Jia, Vincent G DeMarco. Am J Physiol Heart Circ Physiol 2014
68
7


Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2.
Nina Wronkowitz, Sven W Görgens, Tania Romacho, Laura A Villalobos, Carlos F Sánchez-Ferrer, Concepción Peiró, Henrike Sell, Jürgen Eckel. Biochim Biophys Acta 2014
83
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.